Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MRG002 |
Synonyms | |
Therapy Description |
MRG002 consists of a humanized anti-ERBB2 (HER2) IgG1 antibody in conjugation with a cytotoxic agent monomethyl auristatin E (MMAE), which may have antitumor activity against ERBB2 (HER2)-positive tumors (Journal of Clinical Oncology 38, no. 15_suppl, Abstract TPS1101). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MRG002 | MRG 002|MRG-002 | HER2 (ERBB2) Antibody 72 | MRG002 consists of a humanized anti-ERBB2 (HER2) IgG1 antibody in conjugation with a cytotoxic agent monomethyl auristatin E (MMAE), which may have antitumor activity against ERBB2 (HER2)-positive tumors (Journal of Clinical Oncology 38, no. 15_suppl, Abstract TPS1101). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04492488 | Phase Ib/II | MRG002 | A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer | Unknown status | USA | 0 |